In the RUTH study, raloxifene did not affect the incidence of stroke, compared to placebo.
Raloxifene was not genotoxic in any of the extensive battery of test systems applied.
Raloxifene is rapidly absorbed after oral administration, and its absolute bioavailability is 2 percent.
This inhibition is thought to contribute to the drug s effect on bone resorption. Other mechanisms include the suppression of activity of the bone-resorbing cytokine interleukin-6 promoter activity. The AVA is intended for UK users. For example, it increases the density of the vertebrae the bones of the spine and reduces vertebral fracture rates.
Before using this medication, tell your doctor or pharmacist your medical history, especially of blood clots including in the legs lungs eyes , stroke, mini-stroke TIA , heart disease blocked blood vessels in the heart , heart attack, high cholesterol, irregular heartbeat called atrial fibrillation, high blood pressure, smoking, kidney disease, liver disease, heart failure, cancer, high blood fat triglyceride levels caused by estrogen treatment.
Ask your doctor before use if you are taking the following medications:
Maintain adequate respiratory exchange, do not use respiratory stimulants.
Caution is advised if patients receive large doses of ethchlorvynol concurrently.
Combination therapy with didanosine results in higher frequency of these toxicities, and fatalities have been reported in pregnant women.
Continue to take the tablets unless you are advised otherwise by your doctor. Increased risk of deep vein thrombosis and pulmonary embolism has been reported with this drug. Exacerbation of hot flushes Increased incidence of leg pain.